Zota Health Care expands Davaindia network to 2,502 stores nationwide

The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year

Biocon posts strong Q3FY26 growth, boosted by biosimilars & generics

Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore

Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure

Biomica seals exclusive global license for groundbreaking microbiome cancer therapy

The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer

Fitch upgrades Biocon Biologics outlook to positive, affirms ‘BB-’ rating

Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility

Inspection included drug device combinations covering our recent filing in nasal sprays domain

Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’

Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries

Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally

China nod to first homegrown BNCT cancer drug for human trials

The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials